Atea Pharmaceuticals (NASDAQ:AVIR) said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no approved treatment options. During the company’s first-quarter 2026 earnings call, Chief Executive Officer and Founder Dr. Jean-Pierre Sommadossi described the year as “catalyst rich” […]

Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year open-label extension data, while the company remains on track to complete enrollment in its pivotal Phase 3 EMPEROR study in June. On the company’s first-quarter 2026 business and financial update […]

Trevi Therapeutics (NASDAQ:TRVI) management used the company’s first-quarter 2026 earnings call to outline upcoming clinical milestones for its chronic cough programs and to highlight an expanded cash runway following an April equity offering. Clinical program updates and upcoming trial starts President and CEO Jennifer Good said 2026 is “an important year of execution,” and noted […]

Nuvation Bio (NYSE:NUVB) executives said the company made continued commercial progress with ROS1-positive non-small cell lung cancer (NSCLC) therapy Ibtrozi during the first quarter of 2026, pointing to steady new patient demand, a shifting mix toward first-line use, and rising product revenue as more patients remain on treatment longer. Commercial launch trends for Ibtrozi Founder, […]